Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BridgeBio Pharma, Inc. before investing.

In this article, we go over a few key elements for understanding BridgeBio Pharma, Inc.’s stock price such as:

• BridgeBio Pharma, Inc.’s current stock price and volume
• Why BridgeBio Pharma, Inc.’s stock price changed recently
• Upgrades and downgrades for BBIO from analysts
• BBIO’s stock price momentum as measured by its relative strength

About BridgeBio Pharma, Inc. (BBIO)

Before we jump into BridgeBio Pharma, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

Want to learn more about BridgeBio Pharma, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BridgeBio Pharma, Inc..

BridgeBio Pharma, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, BridgeBio Pharma, Inc.’s stock price was $80.090.

BridgeBio Pharma, Inc. is down 2.5% from its previous closing price of $82.140.

During the last market session, BridgeBio Pharma, Inc.’s stock traded between $79.455 and $82.400. Currently, there are approximately 194.79 million shares outstanding for BridgeBio Pharma, Inc..

BridgeBio Pharma, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

BridgeBio Pharma, Inc. Stock Price History

BridgeBio Pharma, Inc.’s (BBIO) price is currently up 7.53% so far this month.

During the month of July, BridgeBio Pharma, Inc.’s stock price has reached a high of $93.420 and a low of $73.560.

Over the last year, BridgeBio Pharma, Inc. has hit prices as high as $93.415 and as low as $42.090. Year to date, BridgeBio Pharma, Inc.’s stock is up 4.71%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BridgeBio Pharma, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there was 1 analyst who downgraded BridgeBio Pharma, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate BridgeBio Pharma, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BridgeBio Pharma, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BridgeBio Pharma, Inc. (BBIO) by visiting AAII Stock Evaluator.

Relative Price Strength of BridgeBio Pharma, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, BridgeBio Pharma, Inc. has a weighted four-quarter relative price strength of 12.53%, which translates to a Momentum Score of 85 and is considered to be Very Strong.

Want to learn more about how BridgeBio Pharma, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BridgeBio Pharma, Inc. Stock Price: Bottom Line

As of July 31, 2026, BridgeBio Pharma, Inc.’s stock price is $80.090, which is down 2.5% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BridgeBio Pharma, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.